Diabetic Foot Ulcer Treatment Market to Touch $11.05 Bn by 2027: Increase in Advanced Treatment Procedures for Wound Care to Bolster Growth

The global diabetic foot ulcer treatment market size is anticipated to hit USD 11.05 billion by the end of 2027, with the rising incidence of diabetes, especially among the geriatric population. According to a report by Fortune Business Insights, titled, “Diabetic Foot Ulcer (DFU) Treatment Market Size, Share & Covid-19 Impact Analysis, By Ulcer Type (Neuropathic Ulcer, Ischemic Ulcer, Neuro-ischemic Ulcer), By Product (Wound-care Dressings, Wound-care Devices, Active Therapies, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings), and Regional Forecasts, 2020-2027,” the market value was USD 7.03 billion in 2019 and is likely to exhibit a CAGR of 5.9% between 2020 to 2027.

Orpyx SI, New Sensory Insoles with Remote Patient Monitoring Launched by Orpyx

A new sensory insole with remote patient monitoring was developed by Orpyx Medical Technologies and launched in December 2019. It is a digital health therapeutic device used by people suffering from neuropathy-related or diabetic foot ulcers. The sole system works by monitoring the temperature, movement, and pressure of the wearer with the help of the real-time alerts that are both audio and video flexible. These alerts voluntarily take actions on the soles and resolve the high-pressure areas, thus saving the patient from suffering a tissue breakdown. The real-time alerts are recorded on a cloud-based dashboard for healthcare providers to refer to and accordingly suggest medication and therapy to the patients. Such innovations are likely to aid in the expansion of the market in the coming years.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/diabetic-foot-ulcer-dfu-treatment-market-101948

Increasing Diabetic Population to Add Impetus to Market

The increasing prevalence of diabetes, rising complications of foot ulcer among the diabetic population, and improving healthcare services are the key drivers promoting the diabetic foot ulcer treatment market growth. Continuous research and development and launch of innovative products by the players are also adding a boost to the market. Additionally, the rising adoption of technologically advanced treatment options, especially in developed nations, is boosting growth.

On the flip side, the high cost of the treatment device and products, coupled with the lack of proper reimbursement policies for the patient pool, may pose major challenges to the market. Despite this, the increasing awareness about the availability of treatment options is likely to bode well for the market and help attract significant revenue in the future.

Coloplast Corp., Smith & Nephew, and ConvaTec Group Plc Holding Prominent Share Owing to Heavy Investments in Research and Development

The global DFU treatment market is dominated by a few players, namely, Smith & Nephew, Coloplast Corp, and ConvaTech Group. Massive investments into robust research and innovative product development activities are the key factors responsible for the dominance of the companies listed above. The other players are engaging in strategic agreements and partnerships to gain a competitive edge in the market.

Key Industry Developments of Diabetic Foot Ulcer Treatment Market Include:

• December 2017 – The Food and Drug Administration (FDA) approved SANUWAVE Health Inc.’s shock wave device called the Dermapace System. It is used for treating diabetic foot ulcers.


• January 2019 – FibDex, a new advanced wound care product was launched in the European market by UPM. The dressing product is made by wood-based nano fibrillar cellulose and received both a CE mark and FDA approval as the first of its kind in the region.

List of  Prominent Players in the Market Include:

• Mölnlycke Health Care AB (Gothenburg, Sweden)


• Coloplast Corp (Humlebaek, Denmark)


• Integra LifeSciences Corporation (New Jersey, United States)


• 3M (Minnesota, United States)


• Cardinal Health. (Ohio, United States)


• Integra LifeSciences Corporation (New Jersey, United States)


• ConvaTec Group Plc (England, U.K.)


• Tissue Regenix (West Yorkshire, U.S.)


• Smith & Nephew (London, U.K.)


• B. Braun Melsungen AG (Melsungen, Germany)


• Other players

Further Report Findings

• North America earned USD 2.79 billion in 2019 and gained the largest DFU treatment market share. High expenditure on medical facilities, high cost of products, and the presence of major players in the region are some of the factors attributed to the dominance of this region.


• Based on segmentation by product type, the wound care dressings segment earned 42.7% share and emerged dominant in 2019. This is owing to the increasing adoption of exudate management, less healing time, and cost-efficiency of the dressing products.

The Global Diabetic Foot Ulcer Treatment Market is classified into: